The Power of Malaria Vaccine Trials Using Controlled Human Malaria Infection

Controlled human malaria infection (CHMI) in healthy human volunteers is an important and powerful tool in clinical malaria vaccine development. However, power calculations are essential to obtain meaningful estimates of protective efficacy, while minimizing the risk of adverse events. To optimize power calculations for CHMI-based malaria vaccine trials, we developed a novel non-linear statistical model for parasite kinetics as measured by qPCR, using data from mosquito-based CHMI experiments in 57 individuals. We robustly account for important sources of variation between and within individuals using a Bayesian framework. Study power is most dependent on the number of individuals in each treatment arm; inter-individual variation in vaccine efficacy and the number of blood samples taken per day matter relatively little. Due to high inter-individual variation in the number of first-generation parasites, hepatic vaccine trials required significantly more study subjects than erythrocytic vaccine trials. We provide power calculations for hypothetical malaria vaccine trials of various designs and conclude that so far, power calculations have been overly optimistic. We further illustrate how upcoming techniques like needle-injected CHMI may reduce required sample sizes.

[1]  T. Bousema,et al.  Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. , 2005, The Netherlands journal of medicine.

[2]  R. Cortese,et al.  ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  R. Sauerwein,et al.  Comparison of Clinical and Parasitological Data from Controlled Human Malaria Infection Trials , 2012, PloS one.

[4]  D. Webster,et al.  Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. , 2005, The Journal of infectious diseases.

[5]  D. Spiegelhalter,et al.  Disease Mapping With WinBUGS and MLwiN, Bayesian Approaches to Clinical Trials and Health Care Evaluation , 2004 .

[6]  D. Webster,et al.  Comparison of Modeling Methods to Determine Liver-to-blood Inocula and Parasite Multiplication Rates During Controlled Human Malaria Infection , 2013, The Journal of infectious diseases.

[7]  R. Sauerwein,et al.  Memory B-Cell and Antibody Responses Induced by Plasmodium falciparum Sporozoite Immunization , 2014, The Journal of infectious diseases.

[8]  Malaria vaccine: WHO position paper-January 2016. , 2016, Releve epidemiologique hebdomadaire.

[9]  S L Hoffman,et al.  Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. , 1997, The Journal of infectious diseases.

[10]  R. Sauerwein,et al.  Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study , 2011, The Lancet.

[11]  J. Palensky,et al.  Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. , 2001, The Journal of infectious diseases.

[12]  Weltgesundheitsorganisation.  World malaria report , 2005 .

[13]  B. Genton,et al.  A review of malaria vaccine clinical projects based on the WHO rainbow table , 2012, Malaria Journal.

[14]  Adrian J F Luty,et al.  Protection against a malaria challenge by sporozoite inoculation. , 2009, The New England journal of medicine.

[15]  S. Hoffman,et al.  Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. , 2007, The Journal of infectious diseases.

[16]  S. Hoffman,et al.  Optimising Controlled Human Malaria Infection Studies Using Cryopreserved P. falciparum Parasites Administered by Needle and Syringe , 2013, PloS one.

[17]  S. D. de Vlas,et al.  Efficacy of preerythrocytic and blood-stage malaria vaccines can be assessed in small sporozoite challenge trials in human volunteers. , 2012, The Journal of infectious diseases.

[18]  Marie-Claude Dubois,et al.  A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. , 2007, Vaccine.

[19]  T. Theander,et al.  The Plasmodium falciparum var gene transcription strategy at the onset of blood stage infection in a human volunteer. , 2009, Parasitology international.

[20]  S. D. de Vlas,et al.  Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. , 2004, The American journal of tropical medicine and hygiene.

[21]  G. van Gemert,et al.  Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity , 2013, Proceedings of the National Academy of Sciences.

[22]  R. Sauerwein,et al.  Experimental human challenge infections can accelerate clinical malaria vaccine development , 2010, Nature Reviews Immunology.

[23]  V. A. Stewart,et al.  Phase 1/2a Study of the Malaria Vaccine Candidate Apical Membrane Antigen-1 (AMA-1) Administered in Adjuvant System AS01B or AS02A , 2009, PloS one.

[24]  K. Marsh,et al.  Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. , 2009, Vaccine.

[25]  D. Webster,et al.  Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. , 2005, The American journal of tropical medicine and hygiene.

[26]  L. Aarons,et al.  Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection , 2002, Parasitology.

[27]  S. Hoffman,et al.  Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites , 2013, The American journal of tropical medicine and hygiene.

[28]  W. Ballou,et al.  Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults. , 2014, Vaccine.

[29]  Kwaku Poku Asante,et al.  Efficacy of RTS,S malaria vaccines: individual-participant pooled analysis of phase 2 data , 2013, The Lancet. Infectious diseases.

[30]  S. Hoffman,et al.  NF135.C10: A New Plasmodium falciparum Clone for Controlled Human Malaria Infections , 2012, The Journal of infectious diseases.

[31]  V. A. Stewart,et al.  Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. , 2009, The Journal of infectious diseases.

[32]  F. Hayden,et al.  Design, recruitment, and microbiological considerations in human challenge studies. , 2015, The Lancet. Infectious diseases.

[33]  Q. Cheng,et al.  Measurement of Plasmodium falciparum growth rates in vivo: a test of malaria vaccines. , 1997, The American journal of tropical medicine and hygiene.

[34]  E. Linders,et al.  Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. , 2001, Molecular and biochemical parasitology.